News and Trends 4 Jul 2022 New home for wet lab incubator in bid to help biotech start-ups and promote life sciences A lab to bring together the hive minds of those addressing the future challenges in healthcare, including biotech start-ups, is set to open at Discovery Park, Kent, U.K. Barclays has selected the location as the home for its latest Eagle Lab, which will open later this year. The labs are a growing national network currently at […] July 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Time Partners closes £30M venture fund to back life sciences startups Time Partners Limited has announced the final closing of its first advised fund, Time Boost Capital I LP, a £30 million ($36.6 million) genomics venture fund to provide match funding to startups graduating from Illumina Accelerator Cambridge, UK. Since opening in July 2020, Illumina Accelerator Cambridge has launched 13 startups focused on harnessing genomics applications […] June 28, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Companies unite to bolster diagnostics for cancer and liver disease Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease and breast cancer have partnered in a bid to bolster noninvasive diagnostics for the conditions. IV Bio-holdings (IVBH), a clinical-stage bio-platform company that conceives, creates and scales first-generation precision health solutions that improves the detection, diagnosis and treatment of disease […] June 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Roquefort Therapeutics buys UK biotech in return for shares Medical biotechnology company, Roquefort Therapeutics, has conditionally agreed to buy UK biotech Oncogeni Ltd in return for shares. Oncogeni develops novel patented cancer medicines, and will receive 50 million shares, worth just under £4 million ($4.9 million). Acquisition In light of the acquisition, Oncogeni co-founder Ajan Reginald will become chief executive of the group, and […] June 22, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Spirea raises £2.4M to develop antibody drug conjugates in cancer Funding of £2.4 million ($2.9 million) has been secured by UK-based company, Spirea Limited, to advance a new generation of antibody drug conjugate (ADC) therapeutics. The company will use the funds to initiate its pipeline of ADCs in the treatment of solid tumors where they say there is a high unmet need. Targeted therapies, especially […] June 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2022 New treatment option available for Dravet syndrome Global biopharma company UCB says the UK’s National Institute for Healthcare Excellence (NICE) has issued a positive Final Appraisal Determination (FAD) for its FINTEPLA (fenfluramine) oral solution. FINTEPLA is used for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. […] June 1, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 Therapeutic RNA company receives additional funding UK biotech company Transine Therapeutics, which is developing a novel class of therapeutic RNAs, has successfully raised £4.6M ($5.8M) in additional seed funding. The financing was led by new investor Epidarex Capital with participation from existing investor the Dementia Discovery Fund (DDF). Transine said the additional funds will enable it to further develop its SINEUP […] May 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 Award to help NRG Therapeutics develop new Parkinson’s and Motor Neuron Disease treatments UK neuroscience company NRG Therapeutics Ltd has received a Biomedical Catalyst (BMC) award to fund preclinical development of its small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders. The £2.68M ($5.8M) early-stage BMC award part-funded by the government-backed agency Innovate UK will support a […] May 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 ANGLE and U.S. urology group to undertake prostate cancer study ANGLE plc has signed a master clinical study agreement with Solaris Health Holdings, LLC and joinder agreements with MidLantic Urology LLC, to collaborate and conduct clinical studies in prostate cancer and as a potential route to market in the U.S. Alongside Solaris affiliate MidLantic Urology, UK-headquartered ANGLE will initiate clinical studies aimed at detecting prostate […] May 31, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2022 Blue Lake Biotechnology RSV vaccine gets FDA fast track U.S. company Blue Lake Biotechnology, Inc. has received U.S. Food and Drug Administration (FDA) Fast Track designation for its respiratory syncytial virus (RSV) intranasal vaccine. The biopharma company, a subsidiary of CyanVac LLC, develops vaccines using a parainfluenza virus 5 (PIV5)-based vector. The FDA Fast Track designation applies to BLB-201, a vaccine for the prevention […] May 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2022 Duke Street Bio enters stage with next-generation cancer therapies The UK startup Duke Street Bio has exited stealth mode with funding to develop PARP enzyme inhibitors that treat cancer by blocking the repair of DNA in tumor cells. London-based Duke Street Bio said Tuesday that it has a portfolio of PARP1 and PARP7 enzyme inhibitors and has raised enough cash to fund its pipeline […] May 25, 2022 - 3 minutesmins - By Susannah Rodgers Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2022 F2G enlists Shionogi to bring antifungal treatment to Europe and Asia The UK company F2G Ltd. has announced a strategic collaboration with Japanese pharmaceutical company Shionogi & Co. Ltd. to develop and commercialize olorofim, an antifungal treatment for invasive fungal infections, in Europe and Asia. The deal centers on olorofim, F2G’s oral antifungal therapy for the treatment of invasive aspergillosis, an infection that can be deadly […] May 19, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email